Skip to content
2000
Volume 11, Issue 5
  • ISSN: 1566-5232
  • E-ISSN: 1875-5631

Abstract

The potential use of the φC31 integrase system in gene therapy opens up the possibilities of new treatments for old diseases. φC31 integrase mediates the integration of plasmid DNA into the chromsomes of mammalian cells in a sequence- specific manner, resulting in robust, long-term transgene expression. In this article, we review how φC31 integrase mediates transgene integration into the genomes of target cells and summarize the recent preclinical applications of the system to gene therapy. These applications encompass in vivo studies in liver and lung, as well as increasing ex vivo uses of the system, including in neural and muscle stem cells, in cord-lining epithelial cells, and for the production of induced pluripotent stem cells. The safety of the φC31 integrase system for gene therapy is evaluated, and its ability to provide treatments for hemophilia is discussed. We conclude that gene therapy strategies utilizing φC31 integrase offer great promise for the development of treatments in the future.

Loading

Article metrics loading...

/content/journals/cgt/10.2174/156652311797415818
2011-10-01
2025-01-11
Loading full text...

Full text loading...

/content/journals/cgt/10.2174/156652311797415818
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test